Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Published clinical research has characterised the compound in controlled trials: a Phase 2 obesity trial reported dose-dependent body-weight change in the study population (Jastreboff et al., 2023), and a separate Phase 2 trial investigated the GIP/GLP-1/glucagon agonist in people with type 2 diabetes (Rosenstock et al., 2023)
Burning or stinging
-1775582746855.png&w=3840&q=75)
Additionally, it slows gastric emptying and influences appetite regulation, which contributes to its effectiveness in weight management
and superoxide dismutase and catalase, which provide antioxidant defense at repair sites
-43% Original price was: 2,999.00.1,699.00Current price is: 1,699.00
reinstated December 2025 (status: monitor closely) States that restrict coverage: Michigan restricted to BMI 40 (morbid obesity) with strict prior authorization criteria
US$ 26.78
:max_bytes(150000):strip_icc()/Common-Symptoms-From-Taking-a-GLP-1-And-How-to-Manage-Them-9e5bb7cee0484522a50dd9d7ce954cc4.jpg)
US$ 25.27
US$ 23.83
US$ 21.98
US$ 20.91
US$ 28.02
US$ 22.66
